The thesis

IRADIMED CORPORATION specializes in MRI-compatible medical devices. The company's revenue growth has slowed to 0.3% YoY. Despite a high gross margin of 7586.0% and net margin of 2670.0%, the conviction score is 19/100, indicating low confidence. The analyst consensus rating is BUY, but the P/E ratio is 45.6x, suggesting high valuation.

Why now

The current macro context of inflation fears and market volatility makes IRADIMED CORPORATION's high valuation and slowing revenue growth more concerning. The carry trade being potentially broken could impact investor sentiment towards high-growth stocks.

What to watch

Investors should watch IRADIMED CORPORATION's upcoming revenue reports to see if growth accelerates. The company's ability to maintain its high margins, currently at 7586.0% gross margin and 2670.0% net margin, is also crucial.

Key risks

IRADIMED CORPORATION faces valuation risk due to its high P/E ratio of 45.6x. Execution risk is also present as the company struggles with slowing revenue growth of 0.3% YoY. Macro risk is a factor as the company operates in the sensitive Healthcare sector.

Theme exposure